Lovastatin Tablet
Product Images NDC 66267-561

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 66267-561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

66267 561 90

Label for Lovastatin 40 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates an oral tablet dosage form with a package count of 90 tablets. Each round white/off-white tablet is engraved with "CTI 143". The NDC on the label is 66267-561-90, and storage instructions advise keeping at controlled temperature 68-77°F.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure diagram of Lovastatin, the active ingredient shown as a molecular formula with detailed bonds and stereochemistry.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered,' showing interactions between lovastatin and various coadministered drugs or grapefruit juice. The table includes columns for the number of subjects, dosing of the coadministered drug or grapefruit juice, dosing of lovastatin, and AUC ratio values comparing lovastatin exposure with and without the coadministered substances.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' comparing the proportion of participants without events over years of follow-up between Lovastatin and placebo groups. The graph shows a greater proportion event-free in the Lovastatin group, indicating a 37% risk reduction (p < 0.001) compared to placebo.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' lists interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, danazol, diltiazem, dronedarone, verapamil, amiodarone, and grapefruit juice with corresponding prescribing recommendations regarding lovastatin use, including contraindications, dose limits, and avoidance advice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.